EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction ( GEJ ), and stomach adenocarcinoma

Weijing Sun iD, Nirmal Veeramachaneni, Raed Al-Rajabi, Rashna Madan, Anup Kasi, Mazin Al-Kasspooles, Joaquina Baranda, Anwaar Saeed, Milind A Phadnis, Andrew K Godwin, Mojtaba Olyaee, Natalie Streeter und 3 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6263 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Weijing Sun und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophageal Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Perioperative chemotherapy/chemoradiation is standard in esophageal/gastric/gastroesophageal junction (GEJ) adenocarcinoma, immune checkpoint inhibitors (ICI) effect in setting of metastatic and postoperatively. This study is to assess ICI + chemotherapy perioperatively.

Methods

Patients with locally advanced (T1N1‐3M0 or T2‐3NanyM0) potentially resectable esophageal/gastric/GEJ adenocarcinoma by PET/EUS/CT and staging‐laparoscopy, were treated preoperative 4 cycles mFOLFOX6 (Oxaliplatin 85 mg/m 2 /Leucovorin 400 mg/m 2 /5‐FU bolus 400 mg/m 2 then infusion 2400 mg/m 2 for 46 h q2weeks) and 3 cycles pembrolizumab (200 mg q3week). Those without distal disease post‐neoadjuvant and eligible for resection underwent surgery. Postoperative treatment was initiated at 4–8 weeks with 4 cycles mFOLFOX and 12 cycles pembrolizumab. The primary objective is pathological response (ypRR with tumor regression score, TRS ≤2). The expression of ICI‐related markers PD‐L1 (CPS), CD8, and CD20 were analyzed before and after preoperative therapy.

Results

Thirty‐seven patients completed the preoperative treatment. Twenty‐nine patients had curative R0 resection. 6/29 (21%; 95% CI: 0.08–0.40) achieved ypCR with TRS 0 in resected patients. 26/29 (90%; 95% CI: 0.73–0.98) had ypRR with TRS ≤2. Twenty‐six patients finished adjuvant therapy with a median 36.3‐month follow‐up. Three patients had recurrence/metastatic disease (at 9‐, 10‐, 22 months enrollment) with one dead at 23 months, and two are still alive at 28 and 36.5 months. The remaining (23/26) are free of disease with 3 years DFS of 88.5% and 3 years OS of 92.3%. There were no unexpected toxicities. Preoperative ICI + chemotherapy enhanced immune responses significantly with increasing expression of PD‐L1 (CPS ≥10, p = 0.0078) and CD8 (>5%, p = 0.0059).

Conclusions

The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long‐time survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEsophageal NeoplasmsAdenocarcinomaHumansB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsEsophagogastric JunctionNeoadjuvant TherapyAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CD8GEJPD-L1adenocarcinomaesophageal gastricimmune checkpoint inhibitor (ICI)pathological response (ypRR)pembrolizumabperioperativetumor regression score (TRS)

Substanzen

B7-H1 AntigenpembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • University of Kansas Cancer Center, Kansas City, Kansas, USA.
  • Cardiothoracic Surgery Division, Department of Surgery, Saint Louis University School of Medicine, Saint Louis, Missouri, USA.
  • Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Division of Surgical Oncology, Department of Surgery, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Hematology-Oncology Division, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Weijing Sun

Förderung

  • NIGMS NIH HHS
  • Merck

Zitieren

APA

Sun, W., Veeramachaneni, N., Al-Rajabi, R., Madan, R., Kasi, A., Al-Kasspooles, M., Baranda, J., Saeed, A., Phadnis, M. A., Godwin, A. K., Olyaee, M., Streeter, N., Nagji, A., Dai, J., & Williamson, S. (2023). A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction ( GEJ ), and stomach adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.6263

Vancouver

Sun W, Veeramachaneni N, Al-Rajabi R, Madan R, Kasi A, Al-Kasspooles M, et al. A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction ( GEJ ), and stomach adenocarcinoma. Cancer Medicine. 2023. doi:10.1002/cam4.6263

BibTeX
@article{Sun2023,
  author = {Sun, Weijing and Veeramachaneni, Nirmal and Al-Rajabi, Raed and Madan, Rashna and Kasi, Anup and Al-Kasspooles, Mazin and Baranda, Joaquina and Saeed, Anwaar and Phadnis, Milind A and Godwin, Andrew K and Olyaee, Mojtaba and Streeter, Natalie and Nagji, Alykhan and Dai, Junqiang and Williamson, Stephen},
  title = {A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction ( GEJ ), and stomach adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6263}
}
Kostenlos starten →